These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 35477466

  • 1. The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study.
    Rynhoud H, Croton C, Henry G, Meler E, Gibson JS, Soares Magalhaes RJ.
    BMC Vet Res; 2022 Apr 27; 18(1):151. PubMed ID: 35477466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study.
    Rynhoud H, Gibson JS, Meler E, Soares Magalhães RJ.
    Front Vet Sci; 2021 Apr 27; 8():631443. PubMed ID: 33681331
    [Abstract] [Full Text] [Related]

  • 5. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis.
    Visser M, Walsh K, King V, Sture G, Caneva L.
    BMC Vet Res; 2022 Mar 17; 18(1):103. PubMed ID: 35300697
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
    Fleck T, Norris L, King V, Lesman S, Gonzales AJ.
    J Vet Pharmacol Ther; 2022 Jul 17; 45(4):380-384. PubMed ID: 35586953
    [Abstract] [Full Text] [Related]

  • 9. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR.
    Vet Dermatol; 2013 Dec 17; 24(6):587-97, e141-2. PubMed ID: 24581322
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
    Yamazaki C, Rosenkrantz W, Griffin C.
    J Small Anim Pract; 2019 Aug 17; 60(8):499-506. PubMed ID: 31257599
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L, Thom N.
    Vet Dermatol; 2024 Aug 17; 35(4):408-417. PubMed ID: 38465482
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.
    Denti D, Caldin M, Ventura L, De Lucia M.
    Vet Dermatol; 2022 Apr 17; 33(2):149-e42. PubMed ID: 35014745
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.